Skip to main content

Advertisement

SpringerLink
Log in

Copy number gain of PIK3CA and MET is associated with poor prognosis in head and neck squamous cell carcinoma

  • Original Article
  • Published:
Virchows Archiv Aims and scope Submit manuscript

Abstract

The incidence of head and neck squamous cell carcinomas is still growing, and the long-term prognosis of advanced disease remains poor. Only a fraction of head and neck cancers are sensitive to the EGFR-inhibitor cetuximab, which is the only registered targeted therapy available today. In several cancers, gene copy number alterations of MET and PIK3CA have been found to be prognostic and predictive for therapy response. The aim of this study was to systematically analyze in head and neck cancers the pathological characteristics and prognostic significance of copy number changes of MET and PIK3CA genes. MET and PIK3CA copy numbers were analyzed by fluorescence in situ hybridization in tumor samples of 152 patients. Expression of EGFR, p16, and Ki67 was studied by immunohistochemistry. High polysomy of PIK3CA (chromosome 3) was found in 20 % of cases and amplification in 4.5 %. Regarding MET, 35 % of cases showed low or high polysomy of the gene (chromosome 7), while no intra-chromosomal amplification of MET was detected. PIK3CA copy number gain (high polysomy or amplification) was significantly associated with shorter disease-specific survival, larger tumor volume, and lower p16 expression. MET copy number gain (low or high polysomy) in tumors was significantly associated with shorter disease-specific survival and lower level of EGFR. PIK3CA and MET may play an important role in oncogenesis of certain specific subtypes of head and neck cancer. There is an urgent need for the development of novel targeted therapies against these tumors associated with poor prognosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359–E386. doi:10.1002/ijc.29210

    Article  CAS  PubMed  Google Scholar 

  2. Leemans CR, Braakhuis BJ, Brakenhoff RH (2011) The molecular biology of head and neck cancer. Nat Rev Cancer 11(1):9–22. doi:10.1038/nrc2982

    Article  CAS  PubMed  Google Scholar 

  3. Specenier P, Vermorken JB (2013) Cetuximab: its unique place in head and neck cancer treatment. Biologics 7:77–90. doi:10.2147/BTT.S43628

    CAS  PubMed  PubMed Central  Google Scholar 

  4. Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zubel A, Celik I, Schlichting M, Koralewski P (2011) Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 22(7):1535–1546. doi:10.1093/annonc/mdq632

    Article  CAS  PubMed  Google Scholar 

  5. Pirker R, Pereira JR, von Pawel J, Krzakowski M, Ramlau R, Park K, de Marinis F, Eberhardt WE, Paz-Ares L, Storkel S, Schumacher KM, von Heydebreck A, Celik I, O'Byrne KJ (2012) EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol 13(1):33–42. doi:10.1016/S1470-2045(11)70318-7

    Article  CAS  PubMed  Google Scholar 

  6. Licitra L, Mesia R, Rivera F, Remenar E, Hitt R, Erfan J, Rottey S, Kawecki A, Zabolotnyy D, Benasso M, Storkel S, Senger S, Stroh C, Vermorken JB (2011) Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. Ann Oncol 22(5):1078–1087. doi:10.1093/annonc/mdq588

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H, Ding M, Bamford S, Cole C, Ward S, Kok CY, Jia M, De T, Teague JW, Stratton MR, McDermott U, Campbell PJ (2015) COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res 43(Database issue):D805–D811. doi:10.1093/nar/gku1075

    Article  PubMed  PubMed Central  Google Scholar 

  8. Fenic I, Steger K, Gruber C, Arens C, Woenckhaus J (2007) Analysis of PIK3CA and Akt/protein kinase B in head and neck squamous cell carcinoma. Oncol Rep 18(1):253–259

    CAS  PubMed  Google Scholar 

  9. Suda T, Hama T, Kondo S, Yuza Y, Yoshikawa M, Urashima M, Kato T, Moriyama H (2012) Copy number amplification of the PIK3CA gene is associated with poor prognosis in non-lymph node metastatic head and neck squamous cell carcinoma. BMC Cancer 12:416. doi:10.1186/1471-2407-12-416

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Perrone F, Lampis A, Orsenigo M, Di Bartolomeo M, Gevorgyan A, Losa M, Frattini M, Riva C, Andreola S, Bajetta E, Bertario L, Leo E, Pierotti MA, Pilotti S (2009) PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol 20(1):84–90. doi:10.1093/annonc/mdn541

    Article  CAS  PubMed  Google Scholar 

  11. de la Rochefordiere A, Kamal M, Floquet A, Thomas L, Petrow P, Petit T, Pop M, Fabbro M, Kerr C, Joly F, Sevin E, Maillard S, Cure H, Weber B, Brunaud C, Minsat M, Gonzague L, Berton-Rigaud D, Aumont M, Gladieff L, Peigneux K, Bernard V, Leroy Q, Bieche I, Margogne A, Nadan AT, Fourchotte V, Diallo A, Asselain B, Plancher C, Armanet S, Beuzeboc P, Scholl S (2015) PIK3CA pathway mutations predictive of poor response following Standard radio chemotherapy +/− Cetuximab in cervical cancer patients. Clin Cancer Res. doi:10.1158/1078-0432.CCR-14-2368

    PubMed  Google Scholar 

  12. Lesko E, Majka M (2008) The biological role of HGF-MET axis in tumor growth and development of metastasis. Front Biosci 13:1271–1280

    Article  CAS  PubMed  Google Scholar 

  13. Trusolino L, Bertotti A, Comoglio PM (2010) MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 11(12):834–848. doi:10.1038/nrm3012

    Article  CAS  PubMed  Google Scholar 

  14. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF (2003) Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4(12):915–925. doi:10.1038/nrm1261

    Article  CAS  PubMed  Google Scholar 

  15. Cappuzzo F, Marchetti A, Skokan M, Rossi E, Gajapathy S, Felicioni L, Del Grammastro M, Sciarrotta MG, Buttitta F, Incarbone M, Toschi L, Finocchiaro G, Destro A, Terracciano L, Roncalli M, Alloisio M, Santoro A, Varella-Garcia M (2009) Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol 27(10):1667–1674. doi:10.1200/JCO.2008.19.1635

    Article  PubMed  PubMed Central  Google Scholar 

  16. Graziano F, Galluccio N, Lorenzini P, Ruzzo A, Canestrari E, D'Emidio S, Catalano V, Sisti V, Ligorio C, Andreoni F, Rulli E, Di Oto E, Fiorentini G, Zingaretti C, De Nictolis M, Cappuzzo F, Magnani M (2011) Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer. J Clin Oncol 29(36):4789–4795. doi:10.1200/JCO.2011.36.7706

    Article  CAS  PubMed  Google Scholar 

  17. Krumbach R, Schuler J, Hofmann M, Giesemann T, Fiebig HH, Beckers T (2011) Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: activation of MET as one mechanism for drug resistance. Eur J Cancer 47(8):1231–1243. doi:10.1016/j.ejca.2010.12.019

    Article  CAS  PubMed  Google Scholar 

  18. Cappuzzo F, Janne PA, Skokan M, Finocchiaro G, Rossi E, Ligorio C, Zucali PA, Terracciano L, Toschi L, Roncalli M, Destro A, Incarbone M, Alloisio M, Santoro A, Varella-Garcia M (2009) MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Ann Oncol 20(2):298–304. doi:10.1093/annonc/mdn635

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Janne PA (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (New York, NY) 316(5827):1039–1043. doi:10.1126/science.1141478

    Article  CAS  Google Scholar 

  20. Kawakami H, Okamoto I, Okamoto W, Tanizaki J, Nakagawa K, Nishio K (2014) Targeting MET amplification as a new oncogenic driver. Cancers 6(3):1540–1552. doi:10.3390/cancers6031540

    Article  PubMed  PubMed Central  Google Scholar 

  21. Schwab R, Petak I, Kollar M, Pinter F, Varkondi E, Kohanka A, Barti-Juhasz H, Schonleber J, Brauswetter D, Kopper L, Urban L (2014) Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement. Lung Cancer 83(1):109–111. doi:10.1016/j.lungcan.2013.10.006

    Article  PubMed  Google Scholar 

  22. Tamás L, Szentkúti G, Eros M, Dános K, Brauswetter D, Szende B, Zsákovics I, Krenács T (2011) Differential biomarker expression in head and neck cancer correlates with anatomical localization. Pathol Oncol Res 17(3):721–727. doi:10.1007/s12253-011-9376-9

    Article  PubMed  Google Scholar 

  23. Szentkuti G, Danos K, Brauswetter D, Kiszner G, Krenacs T, Csako L, Repassy G, Tamas L (2014) Correlations between prognosis and regional biomarker profiles in head and neck squamous cell carcinomas. Pathol Oncol Res. doi:10.1007/s12253-014-9869-4

    PubMed  Google Scholar 

  24. Lewis JS Jr, Chernock RD (2014) Human papillomavirus and Epstein Barr virus in head and neck carcinomas: suggestions for the new WHO classification. Head Neck Pathol 8(1):50–58. doi:10.1007/s12105-014-0528-6

    Article  PubMed  PubMed Central  Google Scholar 

  25. Lewis JS Jr, Chernock RD, Ma XJ, Flanagan JJ, Luo Y, Gao G, Wang X, El-Mofty SK (2012) Partial p16 staining in oropharyngeal squamous cell carcinoma: extent and pattern correlate with human papillomavirus RNA status. Mod Pathol 25(9):1212–1220. doi:10.1038/modpathol.2012.79

    Article  CAS  PubMed  Google Scholar 

  26. Hirsch FR, Varella-Garcia M, Bunn PA Jr, Di Maria MV, Veve R, Bremmes RM, Baron AE, Zeng C, Franklin WA (2003) Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 21(20):3798–3807. doi:10.1200/JCO.2003.11.069

    Article  CAS  PubMed  Google Scholar 

  27. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K, Domenichini I, Ludovini V, Magrini E, Gregorc V, Doglioni C, Sidoni A, Tonato M, Franklin WA, Crino L, Bunn PA Jr, Varella-Garcia M (2005) Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97(9):643–655. doi:10.1093/jnci/dji112

    Article  CAS  PubMed  Google Scholar 

  28. Seiwert TY, Jagadeeswaran R, Faoro L, Janamanchi V, Nallasura V, El Dinali M, Yala S, Kanteti R, Cohen EE, Lingen MW, Martin L, Krishnaswamy S, Klein-Szanto A, Christensen JG, Vokes EE, Salgia R (2009) The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res 69(7):3021–3031. doi:10.1158/0008-5472.CAN-08-2881

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Lim YC, Kang HJ, Moon JH (2014) C-Met pathway promotes self-renewal and tumorigenecity of head and neck squamous cell carcinoma stem-like cell. Oral Oncol 50(7):633–639. doi:10.1016/j.oraloncology.2014.04.004

    Article  CAS  PubMed  Google Scholar 

  30. Tanizaki J, Okamoto I, Sakai K, Nakagawa K (2011) Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification. Br J Cancer 105(6):807–813. doi:10.1038/bjc.2011.322

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Cappuzzo F, Varella-Garcia M, Finocchiaro G, Skokan M, Gajapathy S, Carnaghi C, Rimassa L, Rossi E, Ligorio C, Di Tommaso L, Holmes AJ, Toschi L, Tallini G, Destro A, Roncalli M, Santoro A, Janne PA (2008) Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients. Br J Cancer 99(1):83–89. doi:10.1038/sj.bjc.6604439

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, Toschi L, Rogers A, Mok T, Sequist L, Lindeman NI, Murphy C, Akhavanfard S, Yeap BY, Xiao Y, Capelletti M, Iafrate AJ, Lee C, Christensen JG, Engelman JA, Janne PA (2010) Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 17(1):77–88. doi:10.1016/j.ccr.2009.11.022

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Lacroix L, Post SF, Valent A, Melkane AE, Vielh P, Egile C, Castell C, Larois C, Micallef S, Saulnier P, Goulaouic H, Lefebvre AM, Temam S (2014) MET genetic abnormalities unreliable for patient selection for therapeutic intervention in oropharyngeal squamous cell carcinoma. PLoS One 9(1):e84319. doi:10.1371/journal.pone.0084319

    Article  PubMed  PubMed Central  Google Scholar 

  34. Ach T, Zeitler K, Schwarz-Furlan S, Baader K, Agaimy A, Rohrmeier C, Zenk J, Gosau M, Reichert TE, Brockhoff G, Ettl T (2013) Aberrations of MET are associated with copy number gain of EGFR and loss of PTEN and predict poor outcome in patients with salivary gland cancer. Virchows Arch 462(1):65–72. doi:10.1007/s00428-012-1358-0

    Article  CAS  PubMed  Google Scholar 

  35. Du L, Shen J, Weems A, Lu SL (2012) Role of phosphatidylinositol-3-kinase pathway in head and neck squamous cell carcinoma. J Oncol 2012:450179. doi:10.1155/2012/450179

    Article  PubMed  PubMed Central  Google Scholar 

  36. Chiosea SI, Grandis JR, Lui VW, Diergaarde B, Maxwell JH, Ferris RL, Kim SW, Luvison A, Miller M, Nikiforova MN (2013) PIK3CA, HRAS and PTEN in human papillomavirus positive oropharyngeal squamous cell carcinoma. BMC Cancer 13:602. doi:10.1186/1471-2407-13-602

    Article  PubMed  PubMed Central  Google Scholar 

  37. Lui VW, Hedberg ML, Li H, Vangara BS, Pendleton K, Zeng Y, Lu Y, Zhang Q, Du Y, Gilbert BR, Freilino M, Sauerwein S, Peyser ND, Xiao D, Diergaarde B, Wang L, Chiosea S, Seethala R, Johnson JT, Kim S, Duvvuri U, Ferris RL, Romkes M, Nukui T, Kwok-Shing Ng P, Garraway LA, Hammerman PS, Mills GB, Grandis JR (2013) Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov 3(7):761–769. doi:10.1158/2159-8290.CD-13-0103

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Smeets SJ, Braakhuis BJ, Abbas S, Snijders PJ, Ylstra B, van de Wiel MA, Meijer GA, Leemans CR, Brakenhoff RH (2006) Genome-wide DNA copy number alterations in head and neck squamous cell carcinomas with or without oncogene-expressing human papillomavirus. Oncogene 25(17):2558–2564. doi:10.1038/sj.onc.1209275

    Article  CAS  PubMed  Google Scholar 

  39. Szabo B, Nelhubel GA, Karpati A, Kenessey I, Jori B, Szekely C, Petak I, Lotz G, Hegedus Z, Hegedus B, Fule T, Dome B, Timar J, Tovari J (2011) Clinical significance of genetic alterations and expression of epidermal growth factor receptor (EGFR) in head and neck squamous cell carcinomas. Oral Oncol 47(6):487–496. doi:10.1016/j.oraloncology.2011.03.020

    Article  CAS  PubMed  Google Scholar 

  40. Bernardes VF, Gleber-Netto FO, Sousa SF, Rocha RM, Aguiar MC (2013) EGFR status in oral squamous cell carcinoma: comparing immunohistochemistry, FISH and CISH detection in a case series study. BMJ Open 3(1). doi:10.1136/bmjopen-2012-002077

  41. Ang KK, Sturgis EM (2012) Human papillomavirus as a marker of the natural history and response to therapy of head and neck squamous cell carcinoma. Semin Radiat Oncol 22(2):128–142. doi:10.1016/j.semradonc.2011.12.004

    Article  PubMed  Google Scholar 

  42. Cancer Genome Atlas N (2015) Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 517(7536):576–582. doi:10.1038/nature14129

    Article  Google Scholar 

Download references

Author information

Author notes

    Authors and Affiliations

    1. MTA-SE Pathobiochemistry Research Group, 1094, Budapest, Tűzoltó Str. 37-47, Hungary

      Diána Brauswetter, Bianka Gurbi, Éva Fruzsina Félegyházi & István Peták

    2. Department of Oto-Rhino-Laryngology, Head and Neck Surgery, Semmelweis University, 1083, Budapest, Szigony Str. 36, Hungary

      Kornél Dános, Ede Birtalan & László Tamás

    3. Department of Pathology and Experimental Cancer Research, Semmelweis University, 1085, Budapest, Üllői Str. 26, Hungary

      Nóra Meggyesházi & Tibor Krenács

    4. MTA-SE Tumor Progression Research Group, 1085, Budapest, Üllői Str. 26, Hungary

      Tibor Krenács

    Authors
    1. Diána Brauswetter
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Kornél Dános
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Bianka Gurbi
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Éva Fruzsina Félegyházi
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Ede Birtalan
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. Nóra Meggyesházi
      View author publications

      You can also search for this author in PubMed Google Scholar

    7. Tibor Krenács
      View author publications

      You can also search for this author in PubMed Google Scholar

    8. László Tamás
      View author publications

      You can also search for this author in PubMed Google Scholar

    9. István Peták
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Diána Brauswetter.

    Ethics declarations

    Conflict of interest

    The authors declare that they have no conflict of interest.

    Additional information

    László Tamás and István Peták contributed equally to this work.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Brauswetter, D., Dános, K., Gurbi, B. et al. Copy number gain of PIK3CA and MET is associated with poor prognosis in head and neck squamous cell carcinoma. Virchows Arch 468, 579–587 (2016). https://doi.org/10.1007/s00428-016-1905-1

    Download citation

    • Received:

    • Revised:

    • Accepted:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s00428-016-1905-1

    Keywords

    Search

    Navigation